*Actinobacillus pleuropneumoniae* is a major cause of pleuropneumonia, an acute or chronic lung disease of pigs that causes significant morbidity, mortality and economic losses in the worldwide pig industry ([@R2], [@R5]). There are 15 established serovars of the bacterium determined by the composition of the capsular polysaccharide ([@R5]) with another proposed based on serology alone ([@R15]). Determining the serovar allows insights into the epidemiology of *A. pleuropneumoniae*, for example, to map outbreaks of disease, to identify introductions of serovars not previously detected in countries and to assist in the formulation of bacterin vaccines. Serovar prevalence varies from country to country and with time ([@R4], [@R6]). For example, currently serovars 5 and 7 dominate in Canada ([@R8]), whereas until the 1990s, it was serovar 1 ([@R6]). In Australia, serovar 15 is highly prevalent ([@R17]) but is rarely reported elsewhere, although it has been recently found in Canada ([@R7]) and possibly also in Japan ([@R10]).

The last prevalence study in the UK analysed *A. pleuropneumoniae* clinical isolates collected in England and Wales between the years 1995 and 2007, with serovar 8 predominant ([@R13]). In that study, serovar was assigned on the basis of PCR amplification of chromosomal capsule-specific regions; immunological serotyping by slide agglutination having been shown erroneously to overestimate serovars 3 and 6 and underestimate serovar 8 prevalence. Similar underestimation and overestimation were also found in a study of Canadian isolates ([@R6]). In this study, the authors sought to determine whether the serotype prevalence of *A. pleuropneumoniae* in England and Wales had changed since 2007 and, in particular, whether new serovars, such as 15, were now present. The isolates evaluated were obtained from clinical cases of diseases in pigs due to *A. pleuropneumoniae* submitted to the Animal Health and Veterinary Laboratories Agency---Weybridge (AHVLA), now the Animal and Plant Health Agency (APHA), or Royal Veterinary College Diagnostic Laboratories. Isolates were collected between 2008 and 2014. For each year, the number of isolates (in brackets) is as follows: 2008 (N=14); 2009 (N=17); 2010 (N=8); 2011 (N=10); 2012 (N=30); 2013 (N=19) and 2014 (N=15). Bacteria were grown on plates comprising Brain Heart Infusion Agar supplemented with 10 µg/ml nicotinamide adenine dinucleotide. Initially, serotyping was assessed by a multiplex PCR that can distinguish between serovars 1--3, 5--8, 10 and 12 ([@R3]). The PCR was based on the authors' original serovar 3--6--8 PCR ([@R18]) but extended to cover all of the serovars reported in England and Wales in the authors' 2010 study ([@R13]) and those reported to be prevalent in Europe and North America ([@R4]). A serovar 15-specific PCR ([@R17]) was subsequently used on strains that were untypable by the 1--3, 5--8, 10 and 12 multiplex PCR. Genomic DNA purified using the QIAamp DNA Mini Kit (Qiagen) or single colonies were used as the source of DNA template for PCR reactions as previously described ([@R3]). In addition to serovar-specific amplicons, the multiplex PCR amplifies a region of the *A. pleuropneumoniae*-specific *apxIVA* gene ([@R16], [@R3]). All isolates investigated in this study produced an *apxIVA* amplicon confirming that they were *A. pleuropneumoniae*. Comparison of the seroprevalence of *A. pleuropneumoniae* in England and Wales in this and the authors' previous study is shown in [Table 1](#VETREC2016103820TB1){ref-type="table"}.

###### 

Percentage serovar distribution of *A. pleuropneumoniae* isolates in England and Wales-based studies

  Percentage of isolates (number of isolates) in range of years indicated                
  ------------------------------------------------------------------------- ------------ -----------
  2                                                                         3.4 (13)       6.2 (7)
  3                                                                         0.5 (2)          --
  6                                                                         10.1 (38)      7.1 (8)
  7                                                                         5.3 (20)       8.0 (9)
  8                                                                         78.0 (295)    71.7 (81)
  12                                                                        2.7 (10)       3.5 (4)
  NT                                                                        --             3.5 (4)

\*[@R13]

†Present study

NT, non-typable

As in the authors' 2010 study, serovar 8 was the most predominant in years 2008--2014 in England and Wales, with a comparatively smaller percentage of serovars 2, 6, 7 and 12. The England and Wales serovar profile contrasts with that found in other European countries. For example, serovar 9/11 predominates in the Czech Republic ([@R11]) and serovar 2 in Denmark ([@R9]), Norway and Sweden ([@R5]). No serovar 3 isolates were found, possibly reflecting the known low virulence of this serotype ([@R14]), and that the *A. pleuropneumoniae* isolates evaluated were from clinically confirmed cases. Four isolates were non-typable (NT) and subsequent PCR testing established that these were not serovar 15 ([@R17]). Due to their low numbers, the NT isolates were not tested further. The NT isolates could be serovars 4, 9/11, 13, 14, the newly described serovar 16 or variants such that the primers used did not anneal to genomic DNA. Among these, only serovar 9 has been previously reported in Great Britain ([@R12]) or Scotland ([@R1]).

In summary, the authors' results suggest that serovar 8 *A. pleuropneumoniae* remains the predominant serovar causing clinical disease outbreaks in England and Wales, as in the authors' previous study. Any vaccine to be used in the UK to prevent disease caused by *A. pleuropneumoniae* should have a component targeting serovar 8 isolates and, for near-maximal coverage, additionally serovars 2, 6, 7 and 12.
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